The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial.
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to explore if, for locally advanced non-small cell lung cancer
patients whose tumors have high levels of PD-L1 (a marker associated with benefits from
immunotherapy), a combination of immunotherapy and a personalized 4-week radiotherapy course
could be more effective than standard treatment, which is a combination of chemotherapy and
radiotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine, Inc.